In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
News|Podcasts|October 19, 2026
ACT Brief: AI Operating Models, Oncology Evidence Trust, and Thyroid Eye Disease Approval
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new video interview , Rajneesh Patil of Syneos Health argues that the real operational value of AI comes from shifting narrow tools into a continuous learning clinical operating system. He says the bottleneck is the lag between signal and action rather than a lack of data, and warns that governance often fails when it is treated as a one-time approval. - In a
new Q&A , Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to turn fragmented oncology data into reliable real-world evidence. They also explain how routine lab markers can stand in for missing health status data, helping researchers recover a more complete picture of hard-to-reach patients. - The FDA
approved Enspryng for adults with thyroid eye disease , making it the first treatment patients can give themselves at home. The approval is mixed, since one of two pivotal trials missed its main goal. In the trial that succeeded, 52.9% of patients with active disease showed reduced eye bulging, compared with 23.4% on placebo.
That’s all for today’s ACT Brief. Join us next time for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
Comparing OpenAI and Mistral on Clinical Trial Matching
3
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
4
Quotient Sciences first-in-human to proof-of-concept studies
5